Miloš Grujić

TALAPRO-2: Miloš Grujić highlights improved quality of life with Talazoparib + Enzalutamide in mCRPC

Miloš Grujić, Head of Department of the subspecialist cabinets at the Center for Radiation Oncology at the University Clinical Center Kragujevac, on LinkedIn:

“New Patient-Reported Outcomes from TALAPRO-2

In the latest results published in The Lancet Oncology, talazoparib + enzalutamide demonstrated a significant delay in quality of life deterioration for men with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).

Median time to GHS/QoL deterioration:

  • 27.1 months vs 19.3 months
  • HR 0.69 (95% CI: 0.49–0.97), p=0.032

This supports the dual aim of treatment:
Prolonging survival while preserving quality of life.
Incorporating patient-reported outcomes is critical in our evolving standards for mCRPC care.

The study also suggested improved outcomes in urinary and pain symptom control, reinforcing the clinical relevance of durable disease control with PARP + ARPI combinations.

Miloš Grujić

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial

Authors: Andre P Fay et al.

Miloš Grujić

More posts featuring Miloš Grujić on OncoDaily.

Alexander Niyazov André P. Fay Arun A. Azad cancer Curtis Dunshee Cynthia G Healy Enzalutamide Fred Saad Jae Young Joung Jan Oldenburg Jane Chang Joan Carles Karim Fizazi mCRPC Miloš Grujić Neal D. Shore Neeraj Agarwal Nobuaki Matsubara OncoDaily Oncology Paul Cislo Peter C.C. Fong Robert J Jones Stefanie Zschäbitz TALAPRO-2 Talazoparib Ugo de Giorgi